A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances
Neuroscience Applied September 1, 2026 Carolina Seybert, Ana Matos Pires, Luís Madeira et al.
The therapeutic benefits of psychedelics for neuropsychiatric conditions have gathered significant attention in Europe and around the world, with treatments using psilocybin, MDMA, and ketamine as notable examples. However, the mind-altering effects of these substances, and the complexity of their regulatory frameworks, both within and outside of therapeutic use, imply careful clinical...